Detalles de la búsqueda
1.
Real-world evidence: Long-term safety of deferiprone in a large cohort of patients with sickle cell disease enrolled in a registry for up to 10 years.
Am J Hematol;
99(6): 1031-1039, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38429922
2.
Efficacy and safety of early-start deferiprone in infants and young children with transfusion-dependent beta thalassemia: Evidence for iron shuttling to transferrin in a randomized, double-blind, placebo-controlled, clinical trial (START).
Am J Hematol;
98(9): 1415-1424, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37401738
3.
The pharmacokinetic and safety profile of single-dose deferiprone in subjects with sickle cell disease.
Ann Hematol;
101(3): 533-539, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34981144
4.
Rational Design of Novel Therapies for Pantothenate Kinase-Associated Neurodegeneration.
Mov Disord;
36(9): 2005-2016, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34002881
5.
Safety and efficacy of early start of iron chelation therapy with deferiprone in young children newly diagnosed with transfusion-dependent thalassemia: A randomized controlled trial.
Am J Hematol;
93(2): 262-268, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29119631
6.
The safety and acceptability of twice-daily deferiprone for transfusional iron overload: A multicentre, open-label, phase 2 study.
Br J Haematol;
197(1): e12-e15, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34931307
7.
Commentary concerning the publication by Zheng X et al.: Metabolic activation of deferiprone mediated by CYP2A6 (Xenobiotica, published online 18 May 2021).
Xenobiotica;
52(3): 332-333, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34596004
8.
Deferiprone-induced agranulocytosis: 20 years of clinical observations.
Am J Hematol;
91(10): 1026-31, 2016 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-27415835
9.
Effects of renal impairment on the pharmacokinetics of orally administered deferiprone.
Br J Clin Pharmacol;
82(4): 994-1001, 2016 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-27276421
10.
Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial.
Ann Neurol;
76(4): 509-21, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25112865
11.
Continuation of deferiprone therapy in patients with mild neutropenia may not lead to a more severe drop in neutrophil count.
Eur J Haematol;
92(4): 337-40, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24330079
12.
Deviating from safety guidelines during deferiprone therapy in clinical practice may not be associated with higher risk of agranulocytosis.
Pediatr Blood Cancer;
61(5): 879-84, 2014 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-24376176
13.
Assessment of iron overload in very young children with limited thalassemia care resources in South China.
Hemoglobin;
38(2): 119-26, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24502375
14.
Rates of severe neutropenia and infection risk in patients treated with deferiprone: 28 years of data.
Blood Adv;
2024 Apr 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-38640437
15.
Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years.
Blood Adv;
7(4): 611-619, 2023 02 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-36018224
16.
Extramedullary haematopoiesis in patients with thalassemia: a cross-sectional description of its prevalence, clinical features and survival.
Hematol Transfus Cell Ther;
2023 Aug 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-37690980
17.
Cardiac iron overload evaluation in thalassaemic patients using T2* magnetic resonance imaging following chelation therapy: a multicentre cross-sectional study.
Hematol Transfus Cell Ther;
45(1): 7-15, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-34090847
18.
Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study.
Blood Adv;
6(4): 1243-1254, 2022 02 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-34847228
19.
The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload.
J Pediatr Hematol Oncol;
32(8): 601-5, 2010 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-20921906
20.
Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial.
Lancet Haematol;
7(6): e469-e478, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32470438